StitchR makes it possible to deliver larger payloads with current vectors, expanding the list of diseases targetable by gene therapies.

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.

Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is a big problem: size.

The Keeneland November Breeding Stock Sale concluded its nine-day run in Lexington Wednesday with vibrant trade from a diverse buying bench leading to across-the-board increases where were highlighted ...

A total of 105 head sold for $8,620,500, with an average of $81,325 and a median of $47,500. The median and average were up ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset——Joint poster with Bachem demonstrates ...

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory ...

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...

Gene mutations have consequences both good and bad—from resistance to conditions like diabetes to susceptibility to certain ...

Zymo’s Quick DNA/RNA Viral MagBead Kit was automated using Analytik Jena’s Cybio FeliX pipetting robot. The CyBio FeliX ...

The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...